EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

Lisa-Maj Christensen iD, Mikkel Runason Simonsen iD, Jonas Faartoft Jensen, Daniel Tuyet Kristensen iD, Karen Dybkær, Kirsten Grønbæk iD, Tarec Christoffer El-Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen iD, Dennis Lund Hansen iD, Marianne Tang Severinsen

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Lisa-Maj Christensen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Vidarabine, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kræftens Bekæmpelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen; and a hybrid regimen on complete remission (CR), overall survival (OS) and event‐free survival (EFS). Patients were identified through the Danish National Pathology Registry and validated according to the 2022 WHO classification. OS was estimated using the Kaplan–Meier estimator, and differences in OS were assessed with the log‐rank test. Inverse probability weighting was used to balance compared groups with respect to age and calendar year. Among the 43 intensively treated WHO 2022 MPAL patients, 25 (58.1%) received ALL regimens, 10 (23.3%) received AML regimens and 8 (18.6%) received hybrid regimens. CR rates by treatment regimen were highest for hybrid regimen (87.5% (95% confidence interval (CI): 47.3%–99.7)), followed by ALL regimen (72% (95% CI: 50.6%–87.5%)) and AML regimen (40% (95% CI: 12.2%–73.8%)). Treatment with hybrid regimens consisting of a fludarabine‐based approach (fludarabine, cytarabine, G‐CSF and idarubicin [FLAG‐IDA], fludarabine, cytarabine, G‐CSF and mitoxantrone [Mito‐FLAG] or fludarabine, etoposide, G‐CSF, mitoxantrone and cytarabine [FLEGMA]) was associated with improved OS and EFS compared to a classic daunorubicin–cytarabine AML regimen ( p = 0.02 and p = 0.002 respectively).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VidarabineAntineoplastic Combined Chemotherapy ProtocolsLeukemia, Biphenotypic, AcuteLeukemia, Myeloid, AcuteHumansFemaleMaleMiddle AgedAdultAgedDenmarkPhenotypeCytarabine

Stichwörter der Autor:innen

MPALmixed phenotype acute leukaemia

Substanzen

VidarabinefludarabineCytarabine

Autor:innen und Institutionen

  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Mathemathical Sciences, Aalborg University, Aalborg, Denmark.
  • Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

ORCID-Profile: Lisa-Maj Christensen, Mikkel Runason Simonsen, Daniel Tuyet Kristensen, Kirsten Grønbæk, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen

Förderung

  • Kræftens Bekæmpelse

Zitieren

APA

Christensen, L. M., Simonsen, M. R., Jensen, J. F., Kristensen, D. T., Dybkær, K., Grønbæk, K., El-Galaly, T. C., Ettrup, M. S., Ommen, H. B., Sørensen, A. L. T., Hansen, D. L., & Severinsen, M. T. (2026). Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification. British Journal of Haematology. https://doi.org/10.1111/bjh.70491

Vancouver

Christensen LM, Simonsen MR, Jensen JF, Kristensen DT, Dybkær K, Grønbæk K, et al. Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification. British Journal of Haematology. 2026. doi:10.1111/bjh.70491

BibTeX
@article{Christensen2026,
  author = {Christensen, Lisa-Maj and Simonsen, Mikkel Runason and Jensen, Jonas Faartoft and Kristensen, Daniel Tuyet and Dybkær, Karen and Grønbæk, Kirsten and El-Galaly, Tarec Christoffer and Ettrup, Marianne Schmidt and Ommen, Hans Beier and Sørensen, Anne Louise Tølbøll and Hansen, Dennis Lund and Severinsen, Marianne Tang},
  title = {Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70491}
}
Kostenlos starten →